{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=2", "query": { "condition": "Adenocarcinoma of Colon", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 705, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T23:56:26.190Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04868773", "title": "Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Colorectal Carcinoma", "Metastatic Cancer", "CRC" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 15, "start_date": "2021-07-16", "completion_date": "2024-04-09", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04868773" }, { "nct_id": "NCT02206360", "title": "Pancreatic Cancer Early Detection Program", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Pancreatic Adenocarcinoma", "Familial Pancreatic Cancer", "BRCA 1/2", "HNPCC", "Lynch Syndrome", "Hereditary Pancreatitis", "FAMMM", "Familial Atypical Multiple Mole Melanoma", "Peutz Jeghers Syndrome" ], "interventions": [ { "name": "Endoscopic Ultrasound", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "White Plains Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 181, "start_date": "2014-04", "completion_date": "2024-08", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 1, "location_summary": "White Plains, New York", "locations": [ { "city": "White Plains", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206360" }, { "nct_id": "NCT04963283", "title": "Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "Colon Cancer", "Colon Adenocarcinoma", "Rectum Cancer", "Rectal Cancer", "Rectal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-06-23", "completion_date": "2027-02-09", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 5, "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Loveland", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04963283" }, { "nct_id": "NCT06102902", "title": "Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Recurrent Colorectal Adenocarcinoma", "Refractory Colorectal Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "BET Bromodomain Inhibitor ZEN-3694", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-06-05", "completion_date": "2027-01-30", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 16, "location_summary": "Costa Mesa, California • Irvine, California • Los Angeles, California + 12 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06102902" }, { "nct_id": "NCT03157128", "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Medullary Thyroid Cancer", "Colon Cancer", "Any Solid Tumor" ], "interventions": [ { "name": "LOXO-292", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 857, "start_date": "2017-05-02", "completion_date": "2027-02", "has_results": true, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 41, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03157128" }, { "nct_id": "NCT06789172", "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours", "Sarcoma", "HNSCC", "Non Small Cell Lung Cancer", "NSCLC", "Colorectal Cancer (CRC)", "Myxofibrosarcoma (MFS)", "Solitary Fibrous Tumors", "Dedifferentiated Liposarcoma", "Undifferentiated Pleomorphic Sarcoma (UPS)", "Leiomyosarcoma", "Leiomyosarcoma (LMS)", "Gastric Cancer (GC)", "Gastric Cancer Adenocarcinoma Metastatic", "Gastric / Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "OKN4395", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Fasting", "type": "OTHER" }, { "name": "Fed", "type": "OTHER" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "Epkin", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2025-01-23", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 3, "location_summary": "Beverly Hills, California • Santa Monica, California • Houston, Texas", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789172" }, { "nct_id": "NCT05592626", "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Genital Neoplasm, Female", "Urogenital Neoplasms", "Lung Neoplasm", "Neoplasms by Site", "Papillomavirus Infection", "Epstein-Barr Virus Infections", "Carcinoma", "Neoplasms", "Vulvar Neoplasms", "Vulvar Diseases", "Abdominal Neoplasm", "NSCLC (Non-small Cell Lung Cancer)", "Colorectal Cancer" ], "interventions": [ { "name": "STAR0602", "type": "DRUG" }, { "name": "Irinotecan (Camptosar)", "type": "COMBINATION_PRODUCT" }, { "name": "Docetaxel (Taxotere)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Marengo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "2023-01-04", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 13, "location_summary": "Sacramento, California • Celebration, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592626" }, { "nct_id": "NCT04907643", "title": "Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Pain", "Visceral Pain", "Gastrointestinal Neoplasms", "Cancer of Gastrointestinal Tract", "Small Intestine Cancer", "Pancreas Cancer", "Liver Cancer", "Colon Cancer", "Biliary Tract Cancer", "Stomach Cancer", "Rectum Cancer", "Peritoneal Cancer", "Gastrointestinal Cancer Metastatic", "Gastrointestinal Cancers - Anus", "Gastrointestinal Cancers - Stomach", "Gastrointestinal Cancers - Colorectal", "Gastrointestinal Cancers - Small Intestine", "Small Intestine Cancer Stage III", "Small Intestine Cancer Stage IV", "Small Intestine Cancer, Recurrent", "Pancreas Cancer, Stage III", "Pancreas Cancer, Stage IV", "Pancreas Cancer, Metastatic", "Pancreas Cancer, Recurrent", "Liver Cancer Stage IIIa", "Liver Cancer Stage IIIb", "Liver Cancer Stage IIIc", "Liver Cancer Stage IV", "Colon Cancer Stage III", "Colon Cancer Stage IV", "Stomach Cancer Stage III", "Stomach Cancer Stage IV", "Stomach Cancer Recurrent", "Rectum Cancer, Recurrent", "Gastrointestinal Cancers - Liver", "Anal Cancer", "Anal Cancer Stage III", "Anal Cancer Stage IV", "Anal Cancer Recurrent", "Anal Cancer Metastatic", "Anal Cancer, Stage IIIA", "Anal Cancer, Stage IIIB", "Appendix Cancer", "Ampullary Cancer", "Bile Duct Cancer", "Bile Duct Cancer Stage III", "Bile Duct Cancer Stage IV", "Bile Duct Cancer Stage IVA", "Bile Duct Cancer Stage IVB", "Bile Duct Cancer Recurrent", "Carcinoid Tumor", "Carcinoid Tumor of Pancreas", "Carcinoid Tumor of Large Intestine", "Carcinoid Tumor of GI System", "Carcinoid Tumor of Colon", "Carcinoid Tumor of Liver", "Carcinoid Tumor of Cecum", "Carcinoid Tumor of Ileum", "Carcinoid Tumor of Rectum", "Carcinoid Tumor of the Small Bowel", "Carcinoid Tumor of the Stomach", "Large Intestine Cancer", "Esophagus Cancer", "Esophagus Cancer, Stage III", "Esophagus Cancer, Stage IV", "Esophagus Cancer, Recurrent", "Gallbladder Cancer", "Gallbladder Cancer Stage III", "Gallbladder Cancer Stage IV", "Gastric (Stomach) Cancer", "Neuroendocrine Tumor", "Peritoneum Cancer", "Rectal Cancer", "Esophagus Cancer, Stage I", "Esophagus Cancer, Stage II", "Gallbladder Cancer Stage I", "Gallbladder Cancer Stage II", "Bile Duct Cancer Stage I", "Bile Duct Cancer Stage II" ], "interventions": [ { "name": "PICO G2 4k", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 360, "start_date": "2021-10-05", "completion_date": "2027-03-16", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04907643" }, { "nct_id": "NCT06885424", "title": "A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Solid Tumor Cancer", "Solid Tumor, Unspecified, Adult", "Colorectal Carcinoma", "Colorectal Carcinoma (CRC)", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "Pancreatic Cancer", "NSCLC", "Mesothelioma", "Ovarian Cancer", "Ovarian Carcinoma", "Head and Neck (HNSCC)", "Head and Neck Cancer", "Renal Cell Carcinoma (Kidney Cancer)", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "No additional intervention administered in this long term follow-up study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-07-31", "completion_date": "2040-03-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 3, "location_summary": "Gilbert, Arizona • Rochester, Minnesota • New York, New York", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06885424" }, { "nct_id": "NCT00336960", "title": "Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "tumor biopsy", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2002-07", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2013-03-05", "last_synced_at": "2026-10-08T23:56:26.190Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00336960" } ] }